Zhao L, Pan XL, Huang JR, Ji CY, Qu YZ, Wang Y, Ye J. Clinical effects of tauroursodeoxycholic acid
vs ursodeoxycholic acid in treatment of liver cirrhosis.
Shijie Huaren Xiaohua Zazhi 2014;
22:4338-4344. [DOI:
10.11569/wcjd.v22.i28.4338]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To evaluate the efficacy and safety of tauroursodeoxycholic acid (TUDCA) vs ursodeoxycholic acid (UDCA) in patients with liver cirrhosis.
METHODS: Forty-eight patients with cirrhosis treated at Wuhan Union Hospital and Hubei Province Xinhua Hospital were enrolled. The patients were randomly divided into either a TUDCA group or a UDCA group. The TUDCA group had four cases receiving liver biopsy and the UDCA group had two cases. Both drugs were administered at a daily dose of 15 mg/(kg·d) in a randomly assigned sequence for a 6 mo period. Clinical, biochemical and histological features were recorded before and after the treatments to assess the clinical effects of TUDCA.
RESULTS: Forty-three patients were included in the final analysis. The TUDCA group had 21 patients and the UDCA group had 22 patients. Before treatment, there were no significant differences in age, sex or blood chemistry parameters between the two groups. After three months of treatment, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase (GGT) and alkaline phosphatase (ALP) levels in the TUDCA group while only AST level in the UDCA group significantly reduced from baseline (P < 0.05). Serum albumin levels significantly increased in both groups (P < 0.05), and serum AST levels decreased more significantly in the TUDCA group than in the UDCA group. After 6 mo of treatment, serum AST, GGT and ALP levels in the TUDCA group while ALT and GGT levels in the UDCA group significantly reduced from baseline (P < 0.05). Serum albumin levels significantly increased in both groups (P < 0.05). Moreover, serum AST and ALP levels in the TUDCA group decreased more significantly than those in the UDCA group. Two patients in the TUDCA group had significant histological relief. Both treatments were well tolerated, and there was no side effect associated with treatment.
CONCLUSION: TUDCA [15 mg/(kg·d)] therapy is safe and appears to be more effective than UDCA in the treatment of liver cirrhosis, particularly in the improvement of biochemical parameters. TUDCA may delay the progression of liver fibrosis.
Collapse